SEC Form 4 · accession 0001209191-19-009482
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander O. Schuth
Officer — COO and Secretary
Period of report
Feb 8, 2019
Accepted (ET)
Feb 12, 2019 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 8, 2019 | S | 2,500 | $18.11 | D | 667,589 | I | See footnote |
| Common StockF4,F3 | Feb 11, 2019 | S | 1,234 | $18.74 | D | 666,355 | I | See footnote |
| Common StockF5,F3 | Feb 11, 2019 | S | 1,266 | $19.35 | D | 665,089 | I | See footnote |
| Common StockF6,F3 | Feb 12, 2019 | S | 800 | $19.73 | D | 664,289 | I | See footnote |
| Common StockF7,F3 | Feb 12, 2019 | S | 1,700 | $20.24 | D | 662,589 | I | See footnote |
| Common Stock | holding | — | — | — | 15,738 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F2The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.26 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee.
- F4The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.18 to $19.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.18 to $19.46 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F6The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.05 to $19.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F7The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.11 to $20.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.